A258250 Stock Overview
CELLGENTEK Co., Ltd. engages in the production of medical analysis equipment and systems.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CELLGENTEK Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,860.00 |
| 52 Week High | ₩6,220.00 |
| 52 Week Low | ₩1,955.00 |
| Beta | 0 |
| 1 Month Change | -34.93% |
| 3 Month Change | 8.33% |
| 1 Year Change | -41.87% |
| 3 Year Change | -79.57% |
| 5 Year Change | -80.93% |
| Change since IPO | -64.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| A258250 | KR Healthcare Services | KR Market | |
|---|---|---|---|
| 7D | 30.3% | 1.9% | 0.5% |
| 1Y | -41.9% | 18.7% | 4.7% |
Return vs Industry: A258250 underperformed the KR Healthcare Services industry which returned 18.7% over the past year.
Return vs Market: A258250 underperformed the KR Market which returned 4.7% over the past year.
Price Volatility
| A258250 volatility | |
|---|---|
| A258250 Average Weekly Movement | 17.5% |
| Healthcare Services Industry Average Movement | 8.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A258250's share price has been volatile over the past 3 months.
Volatility Over Time: A258250's weekly volatility has increased from 10% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | n/a | www.cellgentek.co.kr |
CELLGENTEK Co., Ltd. engages in the production of medical analysis equipment and systems. Its products include FOBI, a device that can image and analyze fluorescent signals from tissues and organisms; CheBIis, which is optimized for western blot research, using the highly efficient cooling CCD camera; and FluoroBox, a nucleic acid bioimaging instrument. It also offers NK cell therapy, an anticancer drug by using gene manipulation NK cell.
CELLGENTEK Co., Ltd. Fundamentals Summary
| A258250 fundamental statistics | |
|---|---|
| Market cap | ₩11.21b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A258250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A258250 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A258250 perform over the long term?
See historical performance and comparison